| Date | Title | Description |
| 09.10.2025 | AviadoBio and UgeneX Therapeutics Announce Exclusive Option-License Agreement to Develop Next Generation Optogenetics Gene Therapy to Restore Vision in Patients with Retinal Disease | LONDON, and SHANGHAI – October 9, 2025 – AviadoBio Ltd. (“AviadoBio”), and UgeneX Therapeutics, today announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational, AAV-based ge... |
| 02.09.2025 | Diagnostics startup Cyted Health secures $44M Series B | Gastrointestinal diagnostics startup Cyted Health has secured $44 million in Series B funding, led by EQT Life Sciences, with Advent Life Sciences and the British Business Bank (formerly British Patient Capital) joining as co-leads. Existin... |
| 02.09.2025 | EQT Life Sciences Leads USD 44 Million Series B Financing in Cyted Health to Accelerate US Expansion | EQT Life Sciences Leads USD 44 Million Series B Financing in Cyted Health to Accelerate US Expansion
Tue, Sep 02, 2025 11:00 CET Report this content
Amsterdam, The Netherlands, September 2, 2025 – EQT Life Sciences is pleased to announce th... |
| 02.09.2025 | Cyted Health: $44 Million Series B Raised For Advancing US Expansion | Cyted Health, known as a leader in the field of gastrointestinal (GI) molecular diagnostics, has completed the first close of its Series B financing round, raising $44 million. This funding is set to play a crucial role in supporting Cyted’... |
| 01.09.2025 | Cambrige’s Cyted Health raises over €37 million to improve early detection and prevention of oesophageal cancer | Cyted Health, a British gastrointestinal (GI) molecular diagnostics company, announced this weekend a first close of €37.5 million in its Series B financing round to accelerate its ongoing US expansion.
The round was led by EQT Life Science... |
| 16.07.2025 | Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment | Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery researc... |
| 01.05.2025 | AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN | LONDON — MAY 1, 2025 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced the completion of the second dose cohort in its... |
| 24.10.2024 | Epitopea Closes USD $31M Pre-Series A Financing | Epitopea, a Cambridge, UK- and Montreal, Canada-based cancer immunotherapeutics company, raised USD $31M in Pre-Series A funding.
Backers included Investissement Québec, adMare BioInnovations, Jonathan Milner, existing investors Advent Life... |
| 19.08.2024 | Revolutionizing Healthcare: Moximed and PayZen Lead the Charge | In the evolving landscape of healthcare, two companies are emerging as beacons of innovation: Moximed and PayZen. Both are tackling significant challenges in the medical field, albeit from different angles. Moximed is addressing the physica... |
| 17.08.2024 | Moximed: $91 Million (Series D) Closed To Improve Knee Osteoarthritis Care | Moximed, an innovative medical device company with a goal of improving the standard of care for people with knee osteoarthritis (OA), announced the closing on $61 million of Series D preferred stock financing with an option to close on up t... |
| 15.08.2024 | Lilly's New Innovation Center: A Beacon for Biotech in Boston | Eli Lilly and Company has unveiled a new chapter in its storied history with the opening of the Lilly Seaport Innovation Center (LSC) in Boston. This state-of-the-art facility is not just a building; it’s a lighthouse guiding the future of ... |
| 13.08.2024 | Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158 | AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression
Psoriasis biomarker panel and PASI scores expected later this year
CAMBRIDGE, Mass., Aug. 13, 2024 /PRNewswire/ -- Artax Biopharma, Inc., a clini... |
| 12.08.2024 | Artax Biopharma: $8 Million Raised To Transform Treatment Of Autoimmune Diseases | Artax Biopharma, a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, announced the closing of an $8 million convertible debt financing, supported by Eli Lilly and Company, Advent Life Science... |
| 06.08.2024 | Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024 | Strong support from existing shareholders which includes Lilly, Advent Life Sciences, Columbus Ventures, Sound Bioventures and Belinda Termeer
CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnol... |
| 12.07.2024 | Beacon Therapeutics Secures $170 Million in Series B Funding for Advancement of Ophthalmic Gene Therapies | Beacon Therapeutics, a pioneering ophthalmic gene therapy company, has achieved a significant milestone by raising a substantial $170 million in Series B funding. This funding round, spearheaded by Forbion and bolstered by the support of Sy... |
| 03.07.2024 | Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies | Financing led by life sciences venture capital firm Forbion, alongside existing investors Syncona and Oxford Science Enterprises, as well as new investors TCGX and Advent Life Sciences
Round will accelerate the development of lead asset AGT... |
| 04.03.2024 | Argá Medtech secures €54 million in oversubscribed series B |
Argá Medtech’s CSE ablation system enables electrophysiologists to treat any region in the heart safely and efficiently using a single, multi-configurable catheter while titrating lesion depths according to the location within the heart. T... |
| 16.09.2022 | French biotech Tridek-One gets €16 million booster to restore the immune balance in patients | Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of... |
| 25.04.2022 | Advancing cancer treatments, medtech startup Epitopea raises £10.3 million | Cambridge-based Epitopea has raised £10.3 million in a seed funding round. The medtech startup is developing off-the-shelf cancer immunotherapies designed to treat a broad patient population. The influx of capital will be used to further ad... |
| 07.07.2021 |
NeRRe Therapeutics raises £20 million in a Series B2 financing round | NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it h... |
| 19.02.2021 | UK VC Advent Life Sciences raises £153M to support companies that translate early-stage research into impactful medicines | Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. Recently, the London-based company has announced that it has closed two new funds with commitments totalling $215 million (approx £153 mill... |
| 18.02.2021 | Advent Life Sciences closes pair of funds totalling $251m | Advent Life Sciences, a transatlantic venture firm focused on life science companies, has closed a pair of new funds tot |
| 18.02.2021 | Advent Life Sciences Closes Two Funds, Totalling $215M | Advent Life Sciences, a London, UK-based transatlantic venture investor focused on building innovative life science companies in the UK, Europe and the US, closed two new funds, at $215m.
These include:
Advent Life Sciences Fund III, the fi... |
| 04.02.2021 | Highlight Therapeutics cierra una ronda de €22,6M liderada por ColumbusLS y AdventLS. Acuden también el CDTI y socios actuales | 04/02/2021
HIGHLIGHT THERAPEUTICS CIERRA UNA RONDA DE €22,6 MILLONES LIDERADA POR COLUMBUS LIFE SCIENCE Y ADVENT LIFE SCIENCE. ACUDEN TAMBIÉN EL CDTI Y SOCIOS ACTUALES.
Highlight Therapeutics ha cerrado una ronda de €22,6 millones liderad... |
| 05.10.2017 | Vestagen Raises $9.5M from Northwell Ventures | Vestagen Protective Technologies, Inc., which develops and markets VESTEX® Active Barrier1 fabric healthcare uniforms, lab coats and patient garments, today announced the closing of a $9.5 million financing. Existing investors Advent Life S... |
| 21.05.2017 | Domain Associates Joins $65M Series B for Iterum | Iterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, today announced that it has clo... |
| 21.05.2017 | Iterum Raises $65M Series B | Iterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, today announced that it has clo... |
| 12.04.2017 | Vestagen Protective Technologies Raises $10M Financing from Northwell Ventures | Vestagen Protective Technologies, Inc. today announced the first closing of a planned $10 million financing. Existing investors Advent Life Sciences and HealthQuest Capital and new investor Northwell Ventures participated in the funding rou... |
| 12.04.2017 | Vestagen Protective Technologies Raises $10M Financing from HealthQuest Capital | Vestagen Protective Technologies, Inc. today announced the first closing of a planned $10 million financing. Existing investors Advent Life Sciences and HealthQuest Capital and new investor Northwell Ventures participated in the funding rou... |
| 08.02.2016 | Daily funding roundup - February 8, 2016 | Hired raised $40M; Xignite received $20.5M; TalentSky announced $10M funding;
Vast, a company wielding big data for the used cars marketplace, raised $14 million in funding from Capital One Growth Ventures. Jaidev Shergill, one of the firm’... |
| 22.12.2015 | Daily funding roundup - December 22, 2015 | Axonics completed $38.5M; Shuttl raised $20M; NextInput Inc., received $8M funding
Motorola Solutions has made a strategic investment in BlueLine Grid, an emerging technology company that previously received an investment from In-Q-Tel, the... |
| 22.09.2015 | La biotecnológica Artax Biopharma cierra una ronda de $10 millones | 22/09/2015
LA BIOTECNOLÓGICA ARTAX BIOPHARMA CIERRA UNA RONDA DE $10 MILLONES.
La startup biotecnológica Artax Biopharma, ha cerrado una ronda de $10 millones (aproximadamente €9 millones) liderada por Henri Termeer, ex Director General d... |
| 06.03.2015 | Ysios Capital invierte en una ronda de $21 millones cerrada por Aura Biosciences | 06/03/2015
YSIOS CAPITAL INVIERTE EN UNA RONDA DE $21 MILLONES CERRADA POR AURA BIOSCIENCES.
La gestora de capital riesgo (venture capital) Ysios Capital ha participado en la ronda de financiación de $21 millones cerrada por la compañía e... |
| 28.10.2014 | Advent joins the parade of new biotech funds with $235M war chest | Advent Life Sciences is joining the parade of new biotech funds debuting this year. Based in London with an investment strategy that reaches into Europe and the U.S., Advent's second dedicated life sciences fund has come up with $235 millio... |
| 28.10.2014 | Advent Life Sciences Closes Venture Capital Fund at £145.5M | London, UK-based Advent Life Sciences has closed its latest venture capital fund at £145.5m ($235m).
Raised from independent financial investors including funds-of-funds, pension funds, and family offices, Advent Life Sciences Fund II focus... |
| - | Advancing cancer treatments, medtech startup Epitopea raises £10.3 million | Cambridge-based Epitopea has raised £10.3 million in a seed funding round. The medtech startup is developing off-the-shelf cancer immunotherapies designed to treat a broad patient population. The influx of capital will be used to further ad... |
| - | Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments | HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing... |
